RANI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rani Therapeutics Holdings Inc is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks clear upward momentum, has mixed financial performance, and no strong proprietary trading signals. While there are some positive developments, such as a new strategic hire and a promising investigational pipeline, the technical indicators and financials suggest caution.
The MACD is negative and contracting, RSI is neutral at 31.264, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 1.086) with resistance at R1: 1.32, showing limited upside potential in the short term.
The appointment of Jesper Hoiland as Head of Strategy brings strong leadership and experience. The investigational pipeline, including RT-114 for obesity, shows promise. The company has cash reserves to fund operations into 2028.
The stock is down 2.78% pre-market, and financial performance in Q4 2025 shows a significant drop in EPS (-74.07% YoY) and gross margin (-100% YoY). Technical indicators do not suggest a strong upward trend.
In Q4 2025, revenue increased by 42.12% YoY to $1.46 million, and net income improved by 15.19% YoY to -$10.31 million. However, EPS dropped significantly by 74.07% YoY, and gross margin fell to 0%.
No analyst rating or price target changes were provided in the data.
